Pitcairn Co. Sells 1,009 Shares of Novo Nordisk A/S (NYSE:NVO)

Pitcairn Co. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,383 shares of the company’s stock after selling 1,009 shares during the quarter. Pitcairn Co.’s holdings in Novo Nordisk A/S were worth $1,713,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. BOKF NA raised its holdings in Novo Nordisk A/S by 31.6% during the 1st quarter. BOKF NA now owns 7,792 shares of the company’s stock valued at $994,000 after acquiring an additional 1,871 shares during the period. Ascent Group LLC grew its position in shares of Novo Nordisk A/S by 4.3% in the first quarter. Ascent Group LLC now owns 19,199 shares of the company’s stock valued at $2,465,000 after purchasing an additional 795 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of Novo Nordisk A/S by 3.4% during the 1st quarter. Captrust Financial Advisors now owns 149,826 shares of the company’s stock valued at $19,238,000 after purchasing an additional 4,947 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in Novo Nordisk A/S by 9.0% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,060 shares of the company’s stock worth $17,213,000 after purchasing an additional 11,020 shares in the last quarter. Finally, Iron Gate Global Advisors LLC boosted its stake in Novo Nordisk A/S by 9.7% in the 1st quarter. Iron Gate Global Advisors LLC now owns 2,410 shares of the company’s stock worth $307,000 after purchasing an additional 214 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NVO shares. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

Shares of Novo Nordisk A/S stock opened at $105.06 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm has a market cap of $471.46 billion, a PE ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The company has a 50 day simple moving average of $115.48 and a two-hundred day simple moving average of $128.80.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.